ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK, NY
Reports Second Quarter 2026 Financial Results and Provides Business Update
Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Axsome Therapeutics Stockholders Approve Director Elections and Auditor Appoi...
Changes in Board, Management or Compensation
Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
Reports First Quarter 2026 Financial Results and Provides Business Update
Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
SEC Staff Correspondence
Correspondence
Submission Upload
Confidential Treatment Order